News >

Biomarker Discovery Leads to Several Targeted Treatments in NSCLC

Caroline Seymour
Published: Thursday, Oct 10, 2019

Wallace L. Akerley, MD, professor of internal medicine and director of the Lung Cancer Disease Center of Excellence at Huntsman Cancer Institute, University of Utah

Wallace L. Akerley, MD

Clinical bias should not play a role in identifying patients with advanced non–small cell lung cancer (NSCLC) who may harbor rare molecular alterations. Rather, patients should undergo broad molecular profiling to determine whether they stand to benefit from the increasing array of highly specific targeted therapies that are showing tremendous responses, said Wallace L. Akerley, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Experts Weigh-In on Emerging Immune Checkpoint Inhibitors and Combination Strategies for Advanced NSCLCNov 30, 20191.5
Burst CME™ – Cancer Summaries and Commentaries: Update from Toronto: Advances in the Treatment of Lung CancersNov 30, 20190.5
Publication Bottom Border
Border Publication